U053 Neonatal Inpatient Consults
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
This session will review a variety of benign and serious neonatal skin conditions seen in the neonatal intensive care unit or nursery. Diagnostic and management strategies will be discussed. The important role that a dermatologist plays in the team caring for the patient will be reviewed.
LEARNING OBJECTIVES
Formulate a differential diagnosis for more benign and serious neonatal skin conditions.
Recognize clinical clues and identify bedside diagnostic tests and other testing that can help make the diagnosis.
Select the most appropriate management strategies for the hospitalized neonate.
SCHEDULE
9:30 PM
Neonatal Inpatient Consults
SPEAKERS
Lucia Zoraida Diaz, MD, FAAD
Raegan D. Hunt, MD, PhD, FAAD
Neha Puar, MD, FAAD
SPEAKER DISCLOSURES
Lucia Zoraida Diaz, MD, FAAD
Janssen Pharmaceuticals, Inc – Investigator(No Compensation Received); Regeneron – Investigator(No Compensation Received); UpToDate, Inc – Other(Honoraria);
Raegan D. Hunt, MD, PhD, FAAD
Chiesi Farmaceutici – Advisory Board(Fees); Dermavant Sciences, Inc. – Advisory Board(Fees); Disc Medicine – Advisory Board(Fees); GlycosBio, Inc – Advisory Board(Stock Options), Stockholder Private Company(Stock); LEO Laboratories Ltd (LEO Pharma) – Advisory Board(Fees); Palvella Therapeutics – Investigator(Fees); Pfizer Inc. – Advisory Board(Fees); Rhythm Pharmaceuticals, Inc. – Investigator(Fees); Timber Pharmaceuticals – Data Safety Monitoring Board(Fees); UpToDate, Inc – Other(Honoraria); Verrica Pharmaceuticals Inc – Advisory Board(Honoraria);
Neha Puar, MD, FAAD
No financial relationships exist with ineligible companies.